Pharmacokinetics in children

No studies have been carried out into the pharmacokinetic parameters of hydrocortisone/oxytetracycline/polymyxin B in children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Systemic use of tetracyclines during tooth development (children under 8 years of age) can cause permanent discolouration and slow down skeletal development. Hypoplasia of the tooth enamel has also been reported. Although it is not likely that these effects will occur after topical use, the possibility should be taken into account. [

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• SENSORY ORGANS
• OTOLOGICALS

CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Reference

1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2008

Changes

Therapeutic Drug Monitoring

Overdose